FOS expression induced by interleukin-1 or acute morphine treatment in the rat hypothalamus is attenuated by chronic exposure to morphine

Brain Research

Volumn 736, Issue 1-2, 1996, Pages 227-236

  Chang, Sulie L ^a   Patel, Nilesh A ^a   Romero, Alejandro A ^a   Thompson, James ^b   Zadina, James E ^c  

^a SETON HALL UNIVERSITY   (United States)

^b LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

caudate putamen; desensitization; FOS immunoreactivity; paraventricular nucleus; supraoptic nucleus

Indexed keywords

INTERLEUKIN 1; MORPHINE; NALOXONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; DESENSITIZATION; GENE EXPRESSION; HYPOTHALAMUS; IMMUNOCYTOCHEMISTRY; MALE; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; PUTAMEN; RAT; SUPRAOPTIC NUCLEUS; THALAMUS MIDLINE NUCLEUS;

EID: 0030583620     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00698-1     Document Type: Article

References (58)

1. [1] Ahmed, M.S., LLanos-Q., J., Dinarello, C.A. and Blatteis, C.M., Interleukin-1 reduces opioid binding in guinea pig brain, Peptides, 6 (1985) 1149-1154.
2. [2] Banks, W.A., Ortiz, L., Plotkin, S.R. and Kastin, A.J., Human interleukin (IL) 1α, murine IL-1α and murine IL-1β are transported from blood to brain in the mouse by a shared saturable mechanism, J. Pharmacol. Exp. Ther., 259 (1991) 988-996.
3. [3] Bateman, A., Singh, A., Kral, T. and Solomon, S., The immune-hypothalamic-pituitary-adrenal axis, Endocr. Rev., 10 (1989) 92-98.
4. [4] Belkowski, S.M., Zhu, J., Liu-Chen, L.-Y., Eisenstein, T.K., Adler, M.A. and Rogers, T.J., Sequence of κ-opioid receptor cDNA in the R 1.1 thymoma cell line, J. Neuroimmunol., 62 (1995) 113-117.
5. [5] Berkenbosch, F., van-Oers, J., del-Rey, A., Tilders, F. and Besedovsky, H., Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1, Science, 238 (1987) 524-526.
6. [6] Brady, L.S., Allison, B.L., Herkenham, M. and Gottesfeld, Z., Systemic interleukin-1 induces early and late patterns of c-fos mRNA expression in brain, J. Neurosci., 14 (1994) 4951-4964.
7. [7] Bryant, H.U., Bernton, E.W. and Holaday, J.W., Immunosuppresive effects of chronic morphine treatment in mice, Life Sci., 41 (1987) 1731-1738.
8. [8] Buckingham, J.C. and Cooper, T.A., Differences in hypothalamic-pituitary-adrenocortical activity in the rat after acute and prolonged treatment with morphine, Neuroendocrinology, 38 (1984) 411-417.
9. [9] Busbridge, N.J. and Grossman, A.B., Stress and the single cytokine: interleukin modulation of the pituitary-adrenal axis, Mol. Cell. Endocrinol., 82 (1991) C209-C214.
10. [10] Bussiere, J.L., Adler, M.W., Rogers, T.J. and Eisenstein, T.K., Cytokine reversal of morphine-induced suppression of the antibody response, J. Pharmacol. Exp. Ther., 264 (1993) 591-597.
11. [11] Chang, S.L., Squinto, S.P. and Harlan, R.E., Morphine activation of c-fos expression in the rat brain, Biochem. Biophys. Res. Commun., 157 (1988) 698-704.
12. [12] Chang, S.L., Ren, T. and Zadina, J.E., Interleukin-1 activation of FOS proto-oncogene protein in the rat hypothalamus, Brain Res., 617 (1993) 123-130.
13. [13] Chang, S.L., Patel, N.A. and Romero, A.A., Activation and desensitization of FOS immunoreactivity in the rat brain following ethanol administration, Brain Res., 679 (1995) 89-98.
14. [14] Chang, S.L., Kenigs, V., Moldow, R.L. and Zadina, J.E., Chronic treatment with morphine and ethanol, but not cocaine, attenuates IL-1β activation of Fos expression in the rat hypothalamic paraventricular nucleus. In B.M. Sharp, T.K. Eisentein, J.J. Madden and H. Friedman (Eds.), The Brain Immune Axis and Substance Abuse, Plenum Press, New York, 1995, pp. 201-208.
15. [15] Chang, S.L., Bersig, J.M., Wu, G.-D., Patel, N.A., Zadina, J.E. and House, S.D., Chronic exposure to morphine attenuates leukocyte-endothelial interactions in the rat mesentery, NIDA Research Monogr., 162 (1995) 189.
16. [16] Chuang, L.F., Chuang, T.K., Killam, K.F.J., Chuang, A.J., Kung, H., Yu, L. and Chuang, R.Y., Delta opioid receptor gene expression in lymphocytes, Biochem. Biophys. Res. Commun., 202 (1994) 1291-1299.
17. [17] Cox, B.M. and Werling, L.L., Opioid tolerance and dependence. In A. Pratt (Ed.), The Biological Bases of Drug Tolerance and Dependence, Academic Press, San Diego, 1991, pp. 199-229.
18. [18] Cunningham, E.T., Jr., Wada, E., Carter, D.B., Tracey, D.E., Battey, J.F. and DeSouza, E.G., In situ histochemical localization of type I interleukin-1 receptor messenger RNA in the central nervous system, pituitary and adrenal gland of the mouse, J. Neurosci., 12 (1992) 1101-1114.
19. [19] Dinarello, C.A., Interleukin-1 and its biologically related cytokines, Adv. Immunol., 44 (1989) 153-205.
20. [20] Dinarello, C.A. and Savage, N., Interleukin-1 and its receptor, Crit. Rev. Immunol., 9 (1989) 1-20.
21. [21] Dinarello, C.A., Interleukin-1 and interleukin-1 antagonism, Blood, 77 (1991) 1627-1652.
22. [22] Dower, S.K., Bird, T.A. and Sims, J.E., Interleukin-1, Adv. Neuroimmunol., 12 (1992) 1-16.
23. [23] Dunn, A.J., Interleukin-1 as a stimulator of hormone secretion, Prog. Neuroendocrinimmunol., 3 (1990) 26-34.
24. [24] Eizirik, D.L., Welsh, M., Strandell, E., Welsh, N. and Sandler, S., Interleukin-1 (β) depletes insulin messenger ribonucleic acid and increases the heat shock protein hsp70 in mouse pancreatic islets without impairing the glucose metabolism, Endocrinology, 127 (1990) 2290-2297.
25. [25] Ericsson, A., Krisztina, J. and Sawchenko, P.E., A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons, J. Neurosci., 14 (1994) 897-913.
26. [26] Farrar, W.L., Kilian, P.L., Ruff, M.R., Hill, J.M. and Pert, C.B., Visualization and characterization of interleukin-1 receptors in brain, J. Immunol., 139 (1987) 459-463.
27. [27] Friedman, W.J., Larkfors, L., Ayer-Lelievre, C., Ebendal, T., Olson, L. and Persson, H., Regulation of β-nerve growth factor expression by inflammatory mediators in hippocampal cultures, J. Neurosci. Res., 27 (1990) 374-382.
28. [28] George, R. and Way, E.L., Studies on the mechanism of pituitary-adrenal activation by morphine, Br. J. Pharmacol. Chemother., 10 (1955) 260-264.
29. [29] Hopkins, S.J. and Rothwell, N.J., Cytokines and the nervous system I: expression and recognition, Trends Neurosci., 18 (1995) 83-88.
30. [30] Hughes, J.H., Colca, J.R., Easom, R.A., Turk, J. and McDaniel, ML., Interleukin-1 inhibits insulin secretion from isolated rat pancreatic islets by a process that requires gene transcription and mRNA translation, J. Clin. Invest., 86 (1990) 856-863.
31. [31] Jacobson, L. and Sapolsky, R., The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis, Endocr. Rev., 12 (1991) 118-134.
32. [32] Katsuura, G., Gottschall, P.E., Dahl, R. and Arimura, A., Adrenocor-ticotropin release induced by intracerebroventricular injection of recombinant human interleukin-1 in rats: possible involvement of prostaglandin, Endocrinology, 122 (1988) 1773-1779.
33. [33] Katsuura, G., Arimura, A., Koves, K. and Gottschall, P.E., Involvement of organum vasculosum of lamina terminalis and preoptic area in interleukin-1β-induced ACTH release, Am. J. Physiol., 258 (1990) E163-E171.
34. [34] Kuhn, C.M. and Windh, R.T., Endocrine actions of opiates. In R.R. Watson, (Ed.), Biochemistry and Physiology of Substance Abuse, Vol. III, CRC Press, Boca Raton, 1989, pp. 247-277.
35. [35] Lawrence, D.M. and Bidlack, J.M., Kappa opioid binding sites on the R1.1 murine lymphoma cell line, J. Neuroimmunol., 41 (1992) 223-230.
36. [36] Lee, S. and Rivier, C., Hypophysiotropic role and hypothalamic gene expression of corticotropin-releasing factor and vasopressin in rats injected with interleukin-1 beta systemically or into the brain ventricles, J. Neuroendocrinol., 6 (1994) 217-223.
37. [37] LeVier, D.G., McCay, J.A., Stern, M.L., Harris, L.S., Page, D. and R.D. Brown, Immunotoxicological profile of morphine sulfate in B6C3F1 female mice, Fundam. Appl. Toxicol., 22 (1994) 525-542.
38. [38] Mansour, A., Khachaturian, H., Lewis, M.E., Akil, H. and Watson, S.J., Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain, J. Neurosci., 7 (1987) 2445-2464.
39. [39] Mansour, A., Fox, C.A., Thompson, R.C., Akil, H. and Watson, S.J., Mu-Opioid receptors mRNA expression in the rat CNS: comparison to mu-receptor binding, Brain Res., 643 (1994) 245-265.
40. [40] Martin, M. and Resch, K., Interleukin-1: more than a mediator between leukocytes, Trends Pharmacol. Sci., 9 (1988) 171-177.
41. [41] Morgan, J.I. and Curran, T., Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun, Annu. Rev. Neurosci., 14 (1991) 421-451.
42. [42] Nakamura, H., Nakanishi, K., Kita, A. and Kadokawa, T., Interleukin-1 induces analgesia in mice by a central action, Eur. J. Pharmacol., 149 (1988) 49-54.
43. [43] Peterson, P.K., Molitor, T.W., Chao, C.C. and Sharp, B., Opiates and cell-mediated immunity. In R.R. Watson, (Ed.), Drugs of Abuse and Immune Function, CRC Press, Boca Raton, 1990, pp. 2-12.
44. [44] Rivest, S. and Rivier, C., Influence of the paraventricular nucleus of the hypothalamus in the alteration of neuroendocrine functions induced by intermittent footshock or interleukin, Endocrinology, 129 (1991) 2049-2057.
45. [45] Rivest, S., Torres, G. and Rivier, C., Differential effects of central and peripheral injection of interleukin-1β on brain c-fos expression and neuroendocrine functions, Brain Res., 587 (1992) 13-23.
46. [46] Rivest, S. and Rivier, C., Interleukin-1β inhibits the endogenous expression of the early gene c-fos located within the nucleus of LH-RH neurons and interferes with hypothalamic LH-RH release during proestrus in the rat, Brain Res., 613 (1993) 132-142.
47. [47] Rothman, R.B., Danks, J.A., Jacobson, A.E., Burke, Jr., T.R., Tortella, T.E. and Holaday, J.W., Morphine tolerance increases μ-noncompetitive κ-binding sites, Eur. J. Pharmacol., 124 (1986) 113-119.
48. [48] Rothwell, N.J., Functions and mechanisms of interleukin-1 in the brain, Trends Pharmacol. Sci., 12 (1991) 430-436.
49. [49] Sauder, D.N. Interleukin-1, Arch. Dermatol., 125 (1989) 679-682.
50. [50] Sapolsky, R., Rivier, C., Yamamoto, G., Plotsky, P. and Vale, W., Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor, Science, 238 (1987) 522-524.
51. [51] Schettini, G., Interleukin-1 in the neuroendocrine system: from gene to function, Prog. Neuroendocrinol. Immunol., 3 (1990) 157-166.
52. [52] Sedqi, M., Roy, S., Ramakrishnan, S., Elde, R. and Loh, H.H., Complementary DNA cloning of a mu-opioid receptor from peritoneal macrophages, Biochem. Biophys. Res. Commun., 209 (1995) 563-574.
53. [53] Shavit, Y., Terman, G.W., Lewis, J.W., Zane, C.J., Gale, R.P. and Liebeskind, J.C., Effects of footshock stress and morphine on natural killer lymphocytes in rats: studies of tolerance and cross-tolerance, Brain Res., 372 (1986) 382-385.
54. [54] Uehara, A., Gottschall, P.E., Dahl, R.R. and Arimura, A., Interleukin-1 stimulates ACTH release by an indirect action which requires endogenous corticotropin releasing factor, Endocrinology, 121 (1987) 1580-1582.
55. [55] Weber, R.J., Ikejiri, B., Rice, K.C., Pert, A. and Hagan, A.A., Opiate receptor mediated regulation of the immune response in vivo, NIDA Research Monogr., 76 (1987) 341-348.
56. [56] Weber, R.J. and Pert, A., The periaqueductal gray matter (PAG) mediates opiate-induced immunosuppression, Science, 245 (1989) 188-190.
57. [57] Wiedermann, C.J., Interleukin-1 interaction with neuroregulatory systems: selective enhancement by recombinant human and mouse interleukin-1 of in vitro opioid peptide receptor binding in rat brain, J. Neurosci. Res., 22 (1988) 172-180.
58. [58] Yasin, S.A., Costa, A., Forsling, M.L. and Grossman, A., Interleukin-1β and interleukin-6 stimulate neurohypophyseal hormone release in vitro, J. Neuroendocrinol., 6 (1994) 179-184.